Evidence map›Paper›PMID 41305358›Full record

Trial reportPathogens (Basel, Switzerland)2025

Exploratory Study on Efficacy and Safety of Minocycline-Based Dual Therapy for

Wen Gao, Jingwen Li, Yuling Tian, Chaoyi Ge, Chi Wang, Jianxiang Liu, Yixuan Li, Hong Cheng

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wen GaoGI Department, Peking University First Hospital, Beijing 100034, China.ORCID 0000-0003-3549-6846
Jingwen LiSchool of Medicine, Tsinghua University, Beijing 100084, China.ORCID 0009-0009-2675-2677
Yuling TianGI Department, Peking University First Hospital, Beijing 100034, China.
Chaoyi GeGI Department, Peking University First Hospital, Beijing 100034, China.
Chi WangGI Department, Peking University First Hospital, Beijing 100034, China.
Jianxiang LiuGI Department, Peking University First Hospital, Beijing 100034, China.
Yixuan LiGI Department, Peking University First Hospital, Beijing 100034, China.
Hong ChengGI Department, Peking University First Hospital, Beijing 100034, China.ORCID 0000-0001-6434-1101

Funding

Beijing Natural Science funding L254077National High Level Hospital Clinical Research Funding (Youth Clinical Research Project of Peking University First Hospital) 2023YC27National High Level Hospital Clinical Research Funding (Youth Clinical Research Project of Peking University First Hospital) 2025YC-GD01
6 · The paper itself

Abstract

BACKGROUND &

aimsThis study aimed to evaluate the feasibility of vonoprazan-minocycline (VM) dual therapy for

methodsIn this open-label RCT, 120

resultsAs first-line treatment, eradication rates were 96.7% (VA) vs. 90.0% (VM) in intention-to-treat (ITT) analysis (

conclusionsVM dual therapy was shown to be an effective and safe treatment option, demonstrating comparable eradication rates to VA dual therapy. While VM had a slightly higher incidence of AEs, they were generally mild and manageable. VM remained a valuable alternative for patients with penicillin allergies or amoxicillin resistance.

Indexed as

Anti-Bacterial AgentsHelicobacter InfectionsHelicobacter pyloriMinocyclinePyrrolesSulfonamidesAdultAgedAmoxicillinDrug Therapy, CombinationFemaleHumansMaleMiddle AgedProton Pump InhibitorsTreatment Outcome1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineAmoxicillinAnti-Bacterial AgentsMinocyclineProton Pump InhibitorsPyrrolesSulfonamidesamoxicillindual therapyHelicobacter pyloriminocyclinetreatmentvonoprazan

Identifiers

PMID41305358
PMCPMC12655117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.